CD274 and non-small cell lung carcinoma: A serious of clinical trials demonstrated that PD-1/PD-L1 inhibitors combined with standard platinum-based chemotherapy significantly improved progression-free survival (PFS) compared with chemotherapy alone.2–4 Albeit, besides Keynote 1895 and 407 studies,6 most phase 3 clinical trials comparing chemotherapy versus ICIs combination approaches for treatment-naive NSCLC treatment designate overall survival as a secondary endpoint, with many lacking comprehensive long-term survival data.